Cohance Lifesciences Reports Q2 FY27 Results with Stronger H2 Growth Visibility
Cohance Lifesciences Ltd 路 Transcript 路 11 Nov 2026, 11:17 pm
Cohance Lifesciences Reports Q2 FY27 Results with Stronger H2 Growth Visibility Cohance Lifesciences posted Q2 FY27 revenue of INR 4,767 million, up 13% QoQ, with adjusted EBITDA rising to INR 458 million (10% margin) and adjusted PAT turning positive. Pharma CDMO revenue grew 34.5% QoQ despite declining 27% YoY, while API+ revenue grew 5% YoY to INR 2,671 million. Specialty Chemicals declined 40.6% YoY to INR 417 million. Management expects H2 FY27 to deliver YoY revenue and EBITDA growth, supported by small molecule reloads, two new commercial programs, and NJ Bio approaching breakeven.
Original exchange filing (PDF)
More announcements from Cohance Lifesciences Ltd
- The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasti Property and Equity Holdings .... 路 12 Nov 2026
- The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasub Property Holdings LLP & Others 路 12 Nov 2026
- Investors Meet 路 11 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasub Property Holdings LLP & Others 路 11 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasti Property and Equity Holdings Pvt Ltd & Others 路 11 Nov 2026
- Investor Presentation 路 07 Nov 2026
- Update on USFDA inspection at Pashamylaram Manufacturing facility. 路 07 Nov 2026
- Audio link for the conference call 路 07 Nov 2026
